Which are the causes of Progressive Supranuclear Palsy?

Progressive Supranuclear Palsy (PSP) is caused by the abnormal accumulation of a protein called tau within brain cells, which leads to the progressive degeneration of specific areas of the brain that control movement, balance, and cognition.

The Pathophysiology of Tauopathy

In a healthy brain, tau proteins act like "railway ties" that stabilize the internal transport tracks (microtubules) within neurons. In Progressive Supranuclear Palsy, these tau proteins undergo a chemical change—hyperphosphorylation—causing them to detach and clump together into insoluble "tangles." These clumps are toxic to neurons, eventually killing the cells. Because Progressive Supranuclear Palsy is a tauopathy, it shares biological similarities with other neurodegenerative conditions, but the specific distribution of these tangles in the midbrain and basal ganglia is what results in the characteristic symptoms like downward gaze palsy and postural instability.

Genetic and Environmental Factors

While the vast majority of cases of Progressive Supranuclear Palsy are sporadic—meaning they occur without a clear family history—researchers have identified specific genetic variations that increase risk. The most significant is the MAPT gene, which provides instructions for making tau protein. Certain variations in this gene, known as the H1 haplotype, are more common in individuals who develop the disease. However, possessing this genetic marker does not guarantee someone will develop Progressive Supranuclear Palsy; it is merely a risk factor rather than a direct cause. Currently, there is no evidence that environmental toxins, viruses, or autoimmune responses are primary triggers for the disease.

Current Research Directions

The exact trigger that causes tau to begin misfolding in Progressive Supranuclear Palsy remains a major focus of ongoing scientific inquiry. Current research is heavily invested in identifying the precise molecular mechanisms that initiate this cascade. Clinical trials are investigating therapies designed to clear these toxic tau aggregates or prevent them from spreading between brain cells, aiming to halt the progression of the disease at its source.

Medical Disclaimer: This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always seek the advice of your neurologist or a qualified health provider with any questions regarding your medical condition.

References

• NIH Genetic and Rare Diseases Information Center (GARD)


• CurePSP (Foundation for PSP/CBD and Related Brain Diseases)


• Orphanet (The portal for rare diseases and orphan drugs)


• Online Mendelian Inheritance in Man (OMIM)